Aeglea Bio Therapeutics (NASDAQ:AGLE) Trading Up 10.6%

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) shares were up 10.6% on Thursday . The company traded as high as $7.84 and last traded at $7.84. Approximately 1,845,719 shares were traded during mid-day trading, an increase of 757% from the average daily volume of 215,450 shares. The stock had previously closed at $7.09.

A number of equities analysts recently commented on AGLE shares. BidaskClub upgraded shares of Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, September 17th. Zacks Investment Research cut Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Aeglea Bio Therapeutics in a report on Wednesday, September 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Aeglea Bio Therapeutics in a research note on Monday, August 10th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $12.31.

The company has a market cap of $349.66 million, a price-to-earnings ratio of -3.33 and a beta of 1.85. The firm’s 50 day simple moving average is $7.07 and its 200-day simple moving average is $7.19.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last posted its earnings results on Monday, August 10th. The biotechnology company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. On average, equities analysts anticipate that Aeglea Bio Therapeutics Inc will post -1.75 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Bank of Montreal Can increased its holdings in shares of Aeglea Bio Therapeutics by 219.1% in the 2nd quarter. Bank of Montreal Can now owns 5,399 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 3,707 shares during the period. BNP Paribas Arbitrage SA grew its position in Aeglea Bio Therapeutics by 150.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 8,073 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 4,849 shares during the last quarter. Citigroup Inc. grew its position in Aeglea Bio Therapeutics by 22.9% during the 1st quarter. Citigroup Inc. now owns 9,355 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,745 shares during the last quarter. Alliancebernstein L.P. acquired a new position in Aeglea Bio Therapeutics in the first quarter valued at $47,000. Finally, Jane Street Group LLC purchased a new stake in shares of Aeglea Bio Therapeutics in the second quarter valued at about $115,000. 85.10% of the stock is owned by institutional investors and hedge funds.

About Aeglea Bio Therapeutics (NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Further Reading: Average Daily Trade Volume – What You Need to Know

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.